Immunosignatures Could Replace Cancer Biomarkers in Early Diagnosis

The study, published in PNAS, showed that the peptide microarrays could classify complex heterogeneous cancers with upto 98% accuracy.

Despite impressive medical strides, cancer remains a leading killer and overwhelming burden to healthcare systems, causing well over a half million fatalities per year with a projected cost of $174 billion by 2020, according to the National Cancer Institute. Reducing the human and economic toll will require diagnosis and intervention at early stages of illness, when the best prognosis for a cure exists.

In recent years, aggressive research and substantial financial investments have been directed at discovering pre-symptomatic indicators of cancer, known as biomarkers. But as lead author Phillip Stafford and his colleagues at Arizona State University's Biodesign Institute emphasize in a new study, the quest for cancer biomarkers has been stymied by a number of factors.

Proceedings of the National Academy of Science

In research appearing in today's issue of the journal , Stafford and his team describe an innovative technique for early disease detection, which they call immunosignaturing.

Read the report here: http://bit.ly/1qfMiZN

Source: MedicalXpress